VHCP Management III, LLC
Follow13F filer, CIK 1738053, New York, NY
VHCP Management III, LLC reported $132,350,000 across 13 holdings for the quarter ended 2018-09-30, in a 13F-HR filed 2018-11-13. Its ten largest share positions make up 98.61% of the portfolio.
Filed (acceptance time not in the bulk data set), ingested 13F-HR 0000950123-18-011333
- Period
- 2018-09-30
- Reported value
- $132M
- Holdings
- 13
- Top 10 weight
- 98.61%
- New
- Sold out
Part of the filer group Venrock Healthcare Capital Partners III, L.P.
Nimish ShahKoh Bong Y
Stakes and trades reported after 2018-09-30
13D, 13G and Form 4 filings by this filer's group, dated after the 13F period, on securities the quarter does not hold as shares.
- OKUR ONKURE THERAPEUTICS INC: 13G 2,309,559 shares, 5.7% of the class, 13G filed 2026-11-20, 0001231919-26-001621Timeline
Accepted , ingested - ENTX ENTERA BIO LTD: 13G 8,861,763 shares, 5.1% of the class, 13G filed 2026-10-30, 0001738048-26-000079Timeline
Accepted , ingested - LYCA LYCIA THERAPEUTICS INC: 13G 6,850,237 shares, 11.9% of the class, 13G filed 2026-10-30, 0001738048-26-000077Timeline
Accepted , ingested - FLSC FRAZIER LIFE SCIENCES ACQ-A: 13G 700,000 shares, 9% of the class, 13G filed 2026-10-27, 0001738048-26-000075Timeline
Accepted , ingested - XFOR X4 PHARMACEUTICALS INC: 13G/A 7,644,072 shares, 7.6% of the class, 13G/A filed 2026-11-16, 0001738048-26-000100Timeline
Accepted , ingested - VOR VOR BIOPHARMA INC: 13G/A 6,443,619 shares, 9.9% of the class, 13G/A filed 2026-11-16, 0001738048-26-000098Timeline
Accepted , ingested - KRRO KORRO BIO INC: 13G/A 1,474,162 shares, 9.9% of the class, 13G/A filed 2026-11-16, 0001738048-26-000096Timeline
Accepted , ingested - JBIO JADE BIOSCIENCES INC: 13G/A 3,858,984 shares, 5.9% of the class, 13G/A filed 2026-11-16, 0001738048-26-000094Timeline
Accepted , ingested - HELP HELUS PHARMA INC: 13G/A 2,688,175 shares, 3.5% of the class, 13G/A filed 2026-11-16, 0001738048-26-000092Timeline
Accepted , ingested - CBIO CRESCENT BIOPHARMA INC.: 13G/A 2,228,641 shares, 5.9% of the class, 13G/A filed 2026-11-16, 0001738048-26-000090Timeline
Accepted , ingested - ACHV ACHIEVE LIFE SCIENCE INC: 13G/A 5,502,064 shares, 5.2% of the class, 13G/A filed 2026-11-16, 0001738048-26-000088Timeline
Accepted , ingested
Holdings, Q3 2018
Share positions as resolved from 13F-HR 0000950123-18-011333, largest first. % of portfolio is the value over $132,350,000, the sum of the share positions whose value is usable for ratios (method).
| Security | History | Shares | Value | % of portfolio | Change | Latest event | Timeline |
|---|---|---|---|---|---|---|---|
| KALVKALVISTA PHARMACEUTICALS INC | 1,284,931 | $28.4M | 21.47% | Timeline | |||
| BCRXBIOCRYST PHARMACEUTICALS INC | 3,061,091 | $23.4M | 17.65% | Timeline | |||
| ObsEva SAObsEva SA | 1,159,789 | $20.9M | 15.8% | ||||
| TRICIDA INCTRICIDA INC | 650,585 | $19.9M | 15.02% | ||||
| ENDOCYTE INCENDOCYTE INC | 600,000 | $10.7M | 8.05% | ||||
| KINIKSA PHARMACEUTICALS LTDKINIKSA PHARMACEUTICALS LTD | 327,777 | $8.36M | 6.32% | ||||
| KADMON HOLDINGS INCKADMON HOLDINGS INC | 2,388,572 | $7.98M | 6.03% | ||||
| MARINUS PHARMACEUTICALS INCMARINUS PHARMACEUTICALS INC | 672,271 | $6.72M | 5.08% | ||||
| BELLEROPHON THERAPEUTICS INCBELLEROPHON THERAPEUTICS INC | 2,274,370 | $2.46M | 1.86% | ||||
| GEMPHIRE THERAPEUTICS INCGEMPHIRE THERAPEUTICS INC | 869,538 | $1.79M | 1.35% | ||||
| APLSAPELLIS PHARMACEUTICALS INC | 50,290 | $894K | 0.68% | Timeline | |||
| CHEMOCENTRYX INCCHEMOCENTRYX INC | 39,036 | $493K | 0.37% | ||||
| CONSTELLATION PHARMACEUTICALCONSTELLATION PHARMACEUTICAL | 66,667 | $449K | 0.34% |
How Q3 2018 was built
Available 13F filings of this filer for the quarter and their roles: the base report is the latest original or restatement, NEW HOLDINGS amendments filed after it are added (method).
| Filing | Role | Amendment | Filed | Accepted | Ingested |
|---|---|---|---|---|---|
| 13F-HR 0000950123-18-011333 | base | 2018-11-13 | acceptance time not in the bulk data set |